TauRx Therapeutics Ltd - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 24

TauRx Therapeutics Ltd – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “TauRx Therapeutics Ltd- Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- TauRx Therapeutics Ltd- Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of TauRx Therapeutics Ltdhuman therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of TauRx Therapeutics Ltdwith complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the TauRx Therapeutics Ltd’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate TauRx Therapeutics Ltd’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of TauRx Therapeutics Ltdin its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the TauRx Therapeutics Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with TauRx Therapeutics Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of TauRx Therapeutics Ltdand identify potential opportunities in those areas.

List of Tables
List of Figures
TauRx Therapeutics Ltd Snapshot
TauRx Therapeutics Ltd Overview
Key Information
Key Facts
TauRx Therapeutics Ltd – Research and Development Overview
Key Therapeutic Areas
TauRx Therapeutics Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
TauRx Therapeutics Ltd – Pipeline Products Glance
TauRx Therapeutics Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
TauRx Therapeutics Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
TauRx Therapeutics Ltd – Drug Profiles
Rember
Product Description
Mechanism of Action
R&D Progress
TRx0014
Product Description
Mechanism of Action
R&D Progress
Anti-Synuclein Program
Product Description
Mechanism of Action
R&D Progress
Next Generation TAIs
Product Description
Mechanism of Action
R&D Progress
TauRx Therapeutics Ltd – Pipeline Analysis
TauRx Therapeutics Ltd – Pipeline Products by Therapeutic Class
TauRx Therapeutics Ltd Pipeline Products By Target
TauRx Therapeutics Ltd – Pipeline Products by Route of Administration
TauRx Therapeutics Ltd – Pipeline Products by Molecule Type
TauRx Therapeutics Ltd – Recent Pipeline Updates
TauRx Therapeutics Ltd – Locations And Subsidiaries
Head Office
Recent Developments
Jul 29, 2008: TauRx Therapeutics Pte. Ltd. & University of Aberdeen Halts Progress Of Alzheimer's Disease For Rember
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• Education Services - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Charter Schools - Global Outlook
• Private Tutoring - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report